Emavusertib hydrochloride is a Small Molecule owned by Aurigene Discovery Technologies, and is involved in 5 clinical trials, of which 4 are ongoing, and 1 is planned.
Emavusertib hydrochloride exhibits therapeutic intervention by inhibiting both interleukin-1 receptor associated kinase-4 (IRAK4) and FLT3. FLT3 (FMS like tyrosine kinase 3) is a member of class III receptor tyrosine kinase family. It is primarily expressed in early myeloid and lymphoid progenitors and plays an important role in cell proliferation and differentiation. The therapeutic candidates by binding to FLT3, inhibit tumor growth and proliferation. IRAK4 is a serine/threonine kinase with tyrosine as a gatekeeper, involved in signaling innate immune responses. This molecule plays an important role in the innate immune system and may also be important for cross-talk between the innate and adaptive immune systems. IRAK4 is required for tumor cell survival and proliferation.
The revenue for Emavusertib hydrochloride is expected to reach a total of $512m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Emavusertib hydrochloride NPV Report.
Emavusertib hydrochloride Overview
Emavusertib hydrochloride is under development for the treatment of diffuse large B cell lymphomas, relapsed or refractory follicular lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia., mantle cell lymphoma, primary CNS lymphoma, non-Hodgkin lymphomas such as Waldenstrom macroglobulinemia and marginal zone lymphoma, hematologic malignancies, gastric cancer, pancreatic ductal adenocarcinoma, melanoma, esophageal cancer and adenocarcinoma of the gastroesophageal junction, non-Hodgkin lymphomas such as myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML) and chronic myelocytic leukemia (CML, chronic myeloid leukemia). It is a small molecule administered orally. The drug candidate targets interleukin-1 receptor-associated kinase-4 (IRAK-4) and FLT3 (FMS like tyrosine kinase 3). It was also under development for the treatment of rheumatoid arthritis and relapsed or refractory acute myelocytic leukemia.
Curis is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating cancers with substantial unmet medical need. The company’s lead product Erivedge has been developed in collaboration with F. Hoffmann-La Roche Ltd and Genentech, which is commercialized for the treatment of advanced basal cell carcinoma (BCC). The product is approved for use in patients with advanced BCC in the US, European Union (EU), Australia and several other countries.
The company reported revenues of (US Dollars) US$10.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 1.7% over FY2020. The operating loss of the company was US$41.2 million in FY2021, compared to an operating loss of US$24.9 million in FY2020. The net loss of the company was US$45.4 million in FY2021, compared to a net loss of US$29.9 million in FY2020. The company reported revenues of US$2.4 million for the second quarter ended June 2022, an increase of 16.3% over the previous quarter.
Quick View – Emavusertib hydrochloride
|Highest Development Stage|